Nationwide surveillance of azole resistance in Aspergillus diseases

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4569-4576

  Vermeulen, Edith ^a   Maertens, Johan ^a,b   De Bel, Annelies ^c   Nulens, Eric ^d   Boelens, Jerina ^e   Surmont, Ignace ^f   Mertens, Anna ^g   Boel, An ^h   Lagrou, Katrien ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^d AZ Sint Jan Brugge Oostende AV ^*  (Belgium)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f Heilig Hart Ziekenhuis   (Belgium)

^g ZNA Middelheim   (Belgium)

^h OLV HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PYRROLE; ANTIFUNGAL AGENT; PYRROLE DERIVATIVE;

ADULT; AGED; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; ASPERGILLOMA; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS BRONCHITIS; BELGIUM; BRONCHITIS; CHRONIC PULMONARY ASPERGILLOSIS; COHORT ANALYSIS; EPIDEMIOLOGICAL DATA; FEMALE; HOSPITAL; HUMAN; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; ANTIFUNGAL RESISTANCE; CLINICAL TRIAL; DRUG EFFECTS; ISOLATION AND PURIFICATION; MIDDLE AGED; PREVALENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; AZOLES; BELGIUM; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES;

EID: 84939832786     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00233-15     Document Type: Article

References (33)

1. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey GA. 2000. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 30:696-709. http://dx.doi.org/10.1086/313756.
2. Vermeulen E, Lagrou K, Verweij PE. 2013. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis 26:493-500. http://dx.doi.org/10.1097/QCO.0000000000000005.
3. Bueid A, Howard SJ, Moore CB, Richardson MD, Harrison E, Bowyer P, Denning DW. 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 65:2116-2118. http://dx.doi.org/10.1093/jac/dkq279.
4. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, Mellado E, Donders AR, Melchers WJ, Verweij PE. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 5:e219. http://dx.doi.org/10.1371/journal.pmed.0050219.
5. van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, Rijnders BJ, Kuijper EJ, van Tiel FH, Varga J, Karawajczyk A, Zoll J, Melchers WJ, Verweij PE. 2013. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 57:513-520. http://dx.doi.org/10.1093/cid/cit320.
6. Mortensen KL, Jensen RH, Johansen HK, Skov M, Pressler T, Howard SJ, Leatherbarrow H, Mellado E, Arendrup MC. 2011. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol 49:2243-2251. http://dx.doi.org/10.1128/JCM.00213-11.
7. Burgel PR, Baixench MT, Amsellem M, Audureau E, Chapron J, Kanaan R, Honoré I, Dupouy-Camet J, Dusser D, Klaassen CH, Meis JF, Hubert D, Paugam A. 2012. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 56:869-874. http://dx.doi.org/10.1128/AAC.05077-11.
8. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, Kuijper EJ, Van Tiel FH, Melchers WJ, Verweij PE. 2011. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 17:1846-1854. http://dx.doi.org/10.3201/eid1710.110226.
9. Morio F, Aubin GG, Danner-Boucher I, Haloun A, Sacchetto E, Garcia-Hermoso D, Bretagne S, Miegeville M, Le Pape P. 2012. High prevalence of triazole resistance in Aspergillus fumigatus especially mediated by TR/L98Hin a French cohort of patients with cystic fibrosis. J Antimicrob Chemother 67:1870-1873. http://dx.doi.org/10.1093/jac/dks160.
10. Alanio A, Sitterlé E, Liance M, Farrugia C, Foulet F, Botterel F, Hicheri Y, Cordonnier C, Costa JM, Bretagne S. 2011. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother 66:371-374. http://dx.doi.org/10.1093/jac/dkq450.
11. Escribano P, Peláez T, Muñoz P, Bouza E, Guinea J. 2013. Is azole resistance in Aspergillus fumigatus a problem in Spain? Antimicrob Agents Chemother 57:2815-2820. http://dx.doi.org/10.1128/AAC.02487-12.
12. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. 2012. Isolation of multiple-triazole resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 67:362-366. http://dx.doi.org/10.1093/jac/dkr443.
13. Fischer J, van Koningsbruggen-Rietschel S, Rietschel E, Vehreschild MJ, Wisplinghoff H, Krönke M, Hamprecht A. 2014. Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients. J Antimicrob Chemother 69:1533-1536. http://dx.doi.org/10.1093/jac/dku009.
14. Georgiadou SP, Kontoyiannis DP. 2012. The impact of azole resistance on aspergillosis guidelines. Ann N Y Acad Sci 1272:15-22. http://dx.doi.org/10.1111/j.1749-6632.2012.06795.x.
15. Lortholary O, Gangneux JP, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y, Coignard B, Dromer F, Bretagne S, French Mycosis Study Group. 2011. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clin Microbiol Infect 17:1882-1889. http://dx.doi.org/10.1111/j.1469-0691.2011.03548.x.
16. Ramos ER, Jiang Y, Hachem R, Kassis C, Kontoyiannis DP, Raad I. 2011. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles. Oncologist 16:1049-1060. http://dx.doi.org/10.1634/theoncologist.2010-0290.
17. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. 2007. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 44:531-540. http://dx.doi.org/10.1086/510592.
18. Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, Oster RA, Anaissie EJ, Walsh TJ, Schuster MG, Wingard JR, Patterson TF, Ito JI, Williams OD, Chiller T, Pappas PG. 2010. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 50:1559-1567. http://dx.doi.org/10.1086/652768.
19. European Centre for Disease Prevention and Control. 2013. Risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species. European Centre for Disease Prevention and Control, Stockholm, Sweden. http://www.ecdc.europa.eu/en/publications/publications/risk-assessment-impact-environmental-usage-of-triazoles-on-aspergillus-spp-resistance-to-medical-triazoles.pdf.
20. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-1821. http://dx.doi.org/10.1086/588660.
21. Blot SI, Taccone FS, Van den Abeele AM, Bulpa P, Meersseman W, Brusselaers N, Dimopoulos G, Paiva JA, Misset B, Rello J, Vandewoude K, Vogelaers D, AspICU Study Investigators. 2012. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 186:56-64. http://dx.doi.org/10.1164/rccm.201111-1978OC.
22. Bulpa P, Dive A, Sibille Y. 2007. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 30:782-800. http://dx.doi.org/10.1183/09031936.00062206.
23. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, Skov M, Maish W, Mastella G, Participants in the Cystic Fibrosis Foundation Consensus Conference. 2003. Allergic bronchopulmonary aspergillosis in cystic fibrosis - state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 37(Suppl 3):S225-S264. http://dx.doi.org/10.1086/376525.
24. Hope WW, Walsh TJ, Denning DW. 2005. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 43(Suppl 1):S207-S238. http://dx.doi.org/10.1080/13693780400025179.
25. Baxter CG, Dunn G, Jones AM, Webb K, Gore R, Richardson MD, Denning DW. 2013. Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol 132:560-566. http://dx.doi.org/10.1016/j.jaci.2013.04.007.
26. Espinel-Ingroff A, Diekema DJ, Fothergill A, Johnson E, Pelaez T, Pfaller MA, Rinaldi MG, Canton E, Turnidge J. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol 48:3251-3257. http://dx.doi.org/10.1128/JCM.00536-10.
27. Snelders E, Karawajczyk A, Schaftenaar G, Verweij P, Melchers WJ. 2010. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother 54:2425-2430. http://dx.doi.org/10.1128/AAC.01599-09.
28. D'Haese J, Theunissen K, Vermeulen E, Schoemans H, De Vlieger G, Lammertijn L, Meersseman P, Meersseman W, Lagrou K, Maertens J. 2012. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol 50:1258-1263. http://dx.doi.org/10.1128/JCM.06423-11.
29. Bader O, Weig M, Reichard U, Lugert R, Kuhns M, Christner M, Held J, Peter S, Schumacher U, Buchheidt D, Tintelnot K, Groß U, Myko-LabNet-D Partners. 2013. CYP51A-based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany. Antimicrob Agents Chemother 57:3513-3517. http://dx.doi.org/10.1128/AAC.00167-13.
30. Alastruey-Izquierdo A, Mellado E, Peláez T, Pemán J, Zapico S, Alvarez M, Rodríguez-Tudela JL, Cuenca-Estrella M, FILPOP Study Group. 2013. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother 57:3380-3387. http://dx.doi.org/10.1128/AAC.00383-13.
31. Tashiro M, Izumikawa K, Minematsu A, Hirano K, Iwanaga N, Ide S, Mihara T, Hosogaya N, Takazono T, Morinaga Y, Nakamura S, Kurihara S, Imamura Y, Miyazaki T, Nishino T, Tsukamoto M, Kakeya H, Yamamoto Y, Yanagihara K, Yasuoka A, Tashiro T, Kohno S. 2012. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother 56:584-587. http://dx.doi.org/10.1128/AAC.05394-11.
32. Hodiamont CJ, Dolman KM, Ten Berge IJ, Melchers WJ, Verweij PE, Pajkrt D. 2009. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol 47:217-220. http://dx.doi.org/10.1080/13693780802545600.
33. Alanio A, Cabaret O, Sitterlé E, Costa JM, Brisse S, Cordonnier C, Bretagne S. 2012. Azole preexposure affects the Aspergillus fumigatus population in patients. Antimicrob Agents Chemother 56:4948-4950. http://dx.doi.org/10.1128/AAC.05990-11.